Ikarian Capital LLC 13D and 13G filings for Bellicum Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 6:00 pm Unchanged |
2023-12-31 | 13G | Bellicum Pharmaceuticals, Inc. BLCM |
Ikarian Capital LLC | 448,101 4.600% |
0 (Unchanged) |
Filing |
| 2023-02-14 11:02 am Sale |
2022-12-31 | 13G | Bellicum Pharmaceuticals, Inc. BLCM |
Ikarian Capital LLC | 448,101 5.200% |
-48,655 (-9.79%) |
Filing |
| 2022-02-14 4:32 pm Sale |
2021-12-31 | 13G | Bellicum Pharmaceuticals, Inc. BLCM |
Ikarian Capital LLC | 496,756 5.900% |
-3,244 (-0.65%) |
Filing |
| 2021-01-08 9:57 pm Purchase |
2020-12-24 | 13G | Bellicum Pharmaceuticals, Inc. BLCM |
Ikarian Capital LLC | 500,000 9.900% |
500,000 (New Position) |
Filing |